Tickerlog
NASDAQ
$1.35
-51.528
-0.417
Updated Monday 7th of March 2022 04:35:12 AM

Oncocyte Corporation Common Stock

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides custom drug target discovery; assay design, development, and validation; and clinical trial and other testing services for pharmaceutical companies. OncoCyte Corporation has a strategic collaboration with Gruppo Oncologico del Nord-Ovest of Pisa to evaluate DetermaIO as a biomarker for immunotherapy response in metastatic colorectal cancer; and Echelon Diagnostics, Inc. The company was founded in 2009 and is headquartered in Irvine, California.
EBITDA $
ROE -51.528
EPS -0.417
Marketcap$120.8M
Free Cash Flow$
Health Care
Biotechnology: Pharmaceutical Preparations

Top gainers today
Top losers today